Search Images Maps Play YouTube Gmail Drive Calendar More »
Settings | Sign in

GlaxoSmithKline

Is GlaxoSmithKline plc about to bomb?

AOL Money UK - ‎13 hours ago‎
In recent years, GlaxoSmithKline(LSE: GSK) has been a major disappointment for its investors. Its share price has slumped by 12% in the last three years as bribery allegations, the loss of patents on key drugs, and a lack of sufficient replacements ...
See realtime coverage

Does This Upstart Pose a Threat to GlaxoSmithKline?

Motley Fool - ‎May 3, 2016‎
GlaxoSmithKline plc (NYSE:GSK) generates more than $1.2 billion per quarter selling vaccines that are used to treat infectious disease, and one of GlaxoSmithKline's top-selling vaccines is Engerix-B, a vaccine used to prevent the spread of hepatitis B.

The numbers don't lie, GlaxoSmithKline plc is set to beat AstraZeneca plc this year

Motley Fool UK - ‎May 3, 2016‎
GlaxoSmithKline (LSE: GSK) has made a great start to 2016. The company's first-quarter results released at the end of last week, showed that Glaxo is on course to increase earnings by 10% to 12% this year, which is slightly ahead of market expectations.
See realtime coverage

GlaxoSmithKline plc 13.5% Potential Upside Indicated by Barclays Capital

DirectorsTalk Interviews - ‎19 hours ago‎
GlaxoSmithKline plc using EPIC/TICKER code LON:GSK had its stock rating noted as 'Reiterates' with the recommendation being set at 'OVERWEIGHT' today by analysts at Barclays Capital.
See realtime coverage

mouthwash to be life saver for babies

Financial Times - ‎Apr 29, 2016‎
A brand of mouthwash has been reformulated by GlaxoSmithKline into an antiseptic gel that could save hundreds of thousands of lives in the developing world.
See realtime coverage

The Single Most Important Thing About GlaxoSmithKline's Q1 Report

Motley Fool - ‎May 2, 2016‎
GlaxoSmithKline reported its first-quarter earnings results before the U.S. stock market opened for trading on Wednesday, April 27, handily topping Wall Street's expectations.

How Is GlaxoSmithKline's Growth Trending?

Yahoo News - ‎May 2, 2016‎
As discussed earlier, GlaxoSmithKline (GSK) reported a growth of 10.8%, or 6.2 billion pounds, in its 1Q16 revenues. This included an operational growth of 8% and the positive impact of foreign exchange due to the weakening of the pound against all ...
See realtime coverage

Two Stocks within Analysts Review: AbbVie Inc. (NYSE:ABBV) , GlaxoSmithKline PLC (NYSE:GSK)

Street Updates - ‎17 hours ago‎
GlaxoSmithKline PLC (NYSE:GSK) moved in red zone with decline of -0.15 points or -0.35% to $43.14. The company has a market worth of $104.40B.
See realtime coverage

CompaniesGlaxoSmithKline Q1 growth aided by HIV drugs

Financial Times - ‎Apr 27, 2016‎
Sir Andrew Witty began his final year in charge of GlaxoSmithKline with a stronger-than-expected rise in first quarter sales and profits - reinforcing confidence that a turnaround is under way at the UK pharmaceuticals group.

How Did GlaxoSmithKline's Pharmaceutical Segment Perform in 1Q16?

Market Realist - ‎May 2, 2016‎
GlaxoSmithKline's (GSK) pharmaceutical segment has declined substantially in 2015 due to the divestment of its oncology business to Novartis (NVS) in March 2015.

Pharma fight! Should you buy GlaxoSmithKline plc, Smith & Nephew plc or Hutchison China MediTech Limited?

Motley Fool UK - ‎Apr 26, 2016‎
However, GlaxoSmithKline has thrown the kitchen sink at replacing these blockbuster brands to drive group sales higher again.

Average Analyst Rating for GlaxoSmithKline PLC (NYSE:GSK)

B.O.D.Y Confidential - ‎7 minutes ago‎
Wall Street analysts have provided an average broker recommendation of 2.71 on GlaxoSmithKline PLC (NYSE:GSK) shares. The rating is determined by using the average of all analyst recommendations taken into consideration by Zacks Research.

GlaxoSmithKline's Stock Rose on Solid 1Q16 Earnings

Market Realist - ‎Apr 30, 2016‎
GlaxoSmithKline (GSK) reported a 10.8% increase in its top line in its 1Q16 earnings on April 27, 2016. Investors can refer to GlaxoSmithKline: A Must-Read Overview for more information. GlaxoSmithKline met Wall Street analysts' 1Q16 estimates for ...
See realtime coverage

MSF delivers petition of almost 400000 people who demand GlaxoSmithKline and Pfizer cut price of pneumonia vaccine

MSF UK (press release) - ‎Apr 27, 2016‎
Médecins Sans Frontières/Doctors Without Borders (MSF) has today delivered a petition of almost 400,000 signatories to GlaxoSmithKline's (GSK) headquarters in London. The petition demands that the two pharmaceutical companies who produce the ...

GlaxoSmithKline profit falls after Novartis deal

MarketWatch - ‎Apr 27, 2016‎
LONDON--GlaxoSmithKline PLC GSK, -1.04% said net profit fell in the first quarter due to a tough year-earlier comparison, which was boosted by proceeds from its three-way transaction with Novartis AG; taking out that effect, profit rose--partly due to ...

The Week ahead: GlaxoSmithKline plc, BP plc and Standard Chartered plc

Motley Fool UK - ‎Apr 25, 2016‎
Kicking off with GlaxoSmithKline (LSE: GSK), it's the only company to outpace the index over the last 12-month period. Investors finally seem to be buying into the longer-term vision that will see the company maintain the dividend for 2016 and 2017 ...

Analysts Consensus For GlaxoSmithKline (LON:GSK)

Risers & Fallers - ‎May 2, 2016‎
A number of investment brokers have recently updated their price targets on shares of GlaxoSmithKline (LON:GSK). According to the latest broker reports outstanding on Tuesday 3rd of May, 8 analysts have a rating of “strong buy”, 0 analysts “buy”, 18 ...
See realtime coverage

Glaxosmithkline profits provide shot in arm for ftse 100

Daily Mail - ‎Apr 27, 2016‎
London's top flight index was given a shot in the arm from drugs giant GlaxoSmithKline after it drove home a better-than-expected jump in profits and sales.

What This Top Dividend Trust Is Holding Now: GlaxoSmithKline plc, BP plc And Royal Bank of Scotland Group plc

Motley Fool UK - ‎Apr 23, 2016‎
GlaxoSmithKline looks a good example. It has faced headwinds of expiring patents and tight healthcare budgets in recent years, but a number of shareholders - including the redoubtable Neil Woodford - have been critical of how the business has been ...

Have income investors forgotten just how good GlaxoSmithKline plc and Vodafone Group plc really are?

Motley Fool UK - ‎Apr 28, 2016‎
Nobody expects pharmaceuticals giant GlaxoSmithKline (LSE: GSK) to be a share price growth machine, but recent performance has still been patchy.
 -